Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Completed · Phase 2 · Has a placebo group
Conditions studied: COVID-19 Pulmonary Complications, COVID-19
In brief
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
Key facts
- Study ID
- NCT04382586
- Run by
- BeiGene
- People needed
- 63
- Starts
- 2020-07-06
- Expected to finish
- 2021-02-01
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St Jude Medical Center — Fullerton, California, United States
- Medstar Heath Research Institute Medstar Washington Hospital Center — Washington D.C., District of Columbia, United States
- John D Archbold Memorial Hospital — Thomasville, Georgia, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- The Brigham and Womens Hospital, Inc — Boston, Massachusetts, United States
- Rutgers University Hospital — Newark, New Jersey, United States
- Therapeutics Concepts — Houston, Texas, United States
- Joe Arrington Cancer Research and Treatment Center — Lubbock, Texas, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.